title: Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometriod ovarian cancer: the SEER experience from 2004 to 2011.
abstract: OBJECTIVE
  Evaluate the impact of radiotherapy on cause specific survival (CSS) and overall survival (OS) for stage (I-III) clear cell, mucinous, and endometriod ovarian cancer.
  
  
  METHODS
  We analyzed incidence, survival, and treatments from the Surveillance, Epidemiology, and End Results (SEER) Program from 2004 to 2011 for clear cell, mucinous, and endometriod histologies of the ovary for stages (I-III). We examined CSS and OS for all three histologies combined and each histology with relation to the use of adjuvant radiation therapy (RT). Survival analysis was calculated by Kaplan-Meier and log-rank analysis.
  
  
  RESULTS
  CSS was higher in individuals not receiving RT at 5 years (81% vs. 74%) and 10 years (74% vs. 65%, p=0.003). OS was higher in individuals not receiving RT at 5 years (76% vs. 73%) and 10 years (64% vs. 59%, p=0.039). Stage III patients receiving RT had a higher OS at 5 years (54% vs. 44%) and 10 year intervals (36% vs. 30%, p=0.037). Stage III patients with mucinous histology receiving RT had a higher OS at 5 years (50% vs. 36%) and 10 years (45% vs. 26%, p=0.052).
  
  
  CONCLUSIONS
  Those receiving RT had a lower CSS and OS at 5 and 10 years. However, subgroup analysis revealed a benefit of RT in terms of OS for all stage III patients and for stage III patients with mucinous histology.
authors.affiliation: Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. Sagar-c-patel@uiowa.edu.
authors.forename: Sagar C
authors.identifier: http://orcid.org/0000-0002-2675-616X
authors.initials: SC
authors.lastname: Patel
authors.affiliation: Department of Radiation Oncology, Huntsman Cancer Hospital, Salt Lake City, UT, USA.
authors.forename: Jonathan
authors.identifier: http://orcid.org/0000-0001-8406-3380
authors.initials: J
authors.lastname: Frandsen
authors.affiliation: Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.|Department of Radiation Oncology, Stratton VA Medical Center, Albany, NY, USA.
authors.forename: Sudershan
authors.initials: S
authors.lastname: Bhatia
authors.affiliation: Department of Radiation Oncology, Huntsman Cancer Hospital, Salt Lake City, UT, USA.
authors.forename: David
authors.initials: D
authors.lastname: Gaffney
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D018269:Carcinoma, Endometrioid / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D018714:Radiotherapy, Adjuvant; D018426:SEER Program; D013997:Time Factors
keywords: Ovary; Radiation; Survival; Uncommon Histology